A liver‐specific gene expression panel predicts the differentiation status of in vitro hepatocyte models

Dae‐Soo Kim, Jea‐Woon Ryu, Mi‐Young Son, Jung‐Hwa Oh, Kyung‐Sook Chung, Sugi Lee, Jeong‐Ju Lee, Jun‐Ho Ahn, Ju‐Sik Min, Jiwon Ahn, Hyun Mi Kang, Janghwan Kim, Cho‐Rok Jung, Nam‐Soon Kim, Hyun‐Soo Cho – 22 June 2017 – Alternative cell sources, such as three‐dimensional organoids and induced pluripotent stem cell–derived cells, might provide a potentially effective approach for both drug development applications and clinical transplantation.

Long‐term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma

Myron J. Tong, Alexander A. Rosinski, Claiborne T. Huynh, Steven S. Raman, David S.K. Lu – 21 June 2017 – Hepatocellular carcinoma (HCC) is the main cause of mortality in patients with chronic viral hepatitis (CVH). We determined the impact of surveillance and treatments on long‐term outcomes in patients with CVH who developed HCC. Between 1984 and 2014, 333 patients with HCC and with hepatitis B or hepatitis C virus infection were evaluated.

Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus‐endemic population

Jonggi Choi, Seungbong Han, Namkug Kim, Young‐Suk Lim – 19 June 2017 – Most mortalities from liver disease and liver cancer worldwide are attributable to hepatitis B virus (HBV) and hepatitis C virus. Despite remarkable advances in the treatment of HBV over past decades, limited population‐level data are available regarding its impact on burden of liver disease and liver cancer. Mortality data from liver disease and liver cancer were obtained from the national death certificate database of Korea, an HBV‐endemic country, between 1999 and 2013, and were analyzed by Joinpoint analysis.

The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis

Guillaume Wettstein, Jean‐Michel Luccarini, Laurence Poekes, Patrick Faye, Francine Kupkowski, Vanessa Adarbes, Evelyne Defrêne, Céline Estivalet, Xavier Gawronski, Ingrid Jantzen, Alain Philippot, Julien Tessier, Pascale Tuyaa‐Boustugue, Fiona Oakley, Derek A. Mann, Isabelle Leclercq, Sven Francque, Irena Konstantinova, Pierre Broqua, Jean‐Louis Junien – 19 June 2017 – IVA337 is a pan‐peroxisome proliferator‐activated receptor (PPAR) agonist with moderate and well‐balanced activity on the three PPAR isoforms (α, γ, δ).

Critical role of CREBH‐mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells

Takeshi Chida, Masahiko Ito, Kenji Nakashima, Yumi Kanegae, Takuya Aoshima, Shuji Takabayashi, Kazuhito Kawata, Yoshimi Nakagawa, Masahiro Yamamoto, Hitoshi Shimano, Tomokazu Matsuura, Yoshimasa Kobayashi, Takafumi Suda, Tetsuro Suzuki – 16 June 2017 – Mechanisms of hepatic fibrogenesis induced by hepatitis C virus (HCV), one of the leading causes of liver fibrosis, are not fully understood.

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

George V. Papatheodoridis, Ramazan Idilman, George N. Dalekos, Maria Buti, Heng Chi, Florian van Boemmel, Jose Luis Calleja, Vana Sypsa, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Onur Keskın, Nikolaos Gatselis, Bettina E. Hansen, Maria Lehretz, Juan de la Revilla, Savvoula Savvidou, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L.A.

Subscribe to